Quick Answer
RxSight, Inc. reported Net Income Loss of -$38.94 million for the year ending 2025.
- RxSight, Inc. showed a decrease of -41.8% in Net Income Loss from 2024 to 2025.
- This data is from RxSight, Inc.'s annual report (Form 10-K), filed with the SEC on February 25, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: -$16.50 million | Q2 2020: -$12.88 million | Q3 2020: $30.66 million | Q1 2021: -$6.81 million | Q2 2021: -$13.48 million | Q3 2021: -$12.67 million | Q1 2022: -$17.60 million | Q2 2022: -$16.73 million | Q3 2022: -$16.82 million | Q1 2023: -$13.21 million | Q2 2023: -$13.80 million | Q3 2023: -$12.42 million | Q1 2024: -$9.10 million | Q2 2024: -$6.08 million | Q3 2024: -$6.34 million | Q1 2025: -$8.19 million | Q2 2025: -$11.79 million | Q3 2025: -$9.82 million.
- Over the full 6 years of available data (2020 to 2025), RxSight, Inc.'s Net Income Loss has declined by 241.2%.
- Historical annual values: Fiscal year 2025: -$38.94 million | Fiscal year 2024: -$27.46 million | Fiscal year 2023: -$48.61 million | Fiscal year 2022: -$66.76 million | Fiscal year 2021: -$48.69 million | Fiscal year 2020: $27.58 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: